Money & Finance

@Lindsey Krewson This podcast above really educated me regarding .....

@Lindsey Krewson show this to Doug when you get a chance.

Consumer prices edged up 0.1%, according to new CPI data. That effectively cancels out the wage growth from June. But you already knew this.....

Investors would have done much better keeping an eye on Tandem Diabetes Care, a small, promising -- yet still risky -- medical products company that is growing sales, but also losing money. In the first quarter, it sold a few thousand of its next-generation insulin pump, the t:slim X2, and says it needs an installed base of 80,000 pumps to break even on a cash flow basis, though it believes it can hit that milestone some time next year. Because diabetes is a huge growth market, with the incidence of the disease expected to grow 165% in the U.S. by 2050, Tandem has a promising technology that analysts believe, if successful, could challenge Medtronic (NYSE:MDT) for industry leadership. Medtronic offers a competing technology called a continuous glucose monitor (CGM) that tracks a patient's blood sugar over time to let them better manage their disease. As diabetics seek alternatives to insulin injections to regulate their condition, Tandem has partnered with DexCom to bring its insulin pump system (that works with DexCom's monitoring system) to market early next year. The artificial pancreas monitors patients' blood glucose levels and uses an algorithm to know when to deliver an appropriate dose of insulin. At least one analyst thinks highly of Tandem's prospects for being able to grab market share when its system is commercialized. He upgraded the stock, which sent shares soaring. Although Medtronic is many times larger than Tandem, its CGM device is also much larger than Tandem's t:slim X2, and thus more cumbersome. And DexCom's monitors, which work with both systems, can be used for longer periods of time with Tandem's pump, making them more convenient. Also, the need for finger pricks for dosing decisions isn't needed with the t:slim X2 whereas they're still necessary with Medtronic's MiniMed system. While the potential for Tandem Diabetes Care may be more promising than for NII Holdings, it also is a risky proposition. Even though the FDA just approved Tandem's pump with its newest technology that predicts where insulin level needs and adjusts production accordingly, Medtronic also received regulatory approval for its own enhanced CGM system that now allows for treating patients between ages seven and 13. It removes a competitive advantage Tandem had with its pump being able to be used on those as young as six. Tandem's finances are probably not going to look pretty either for awhile yet. Still, by the t:slim X2 getting approved for use with DexCom's more feature-rich monitoring technology, a development that wasn't expected, there's good reason why Tandem Diabetes Care shares are soaring.

The Global Diabetes Care Devices Market is expected to exceed more than US$ 30.25 Billion by 2022 at a CAGR of 5.9% in the given forecast period Browse Full Report:https://www.marketresearchengine.com/diabetes-care-devices-market The Global Diabetes Care Devices Market is segmented on the lines of its glucose monitoring devices, insulin delivery device, type and regional. Based on glucose monitoring device segmentation it covers blood glucose meters, blood glucose test strips, lancing devices, continuous glucose monitoring devices, HbA1c testing kits. Based on insulin delivery device segmentation it covers insulin pumps, insulin syringes and insulin pens. Based on type segmentation it covers therapy type, inject able, oral drugs. The major driving factors of Global Diabetes Care Devices Market are as follows: Increasing prevalence of diabetes care patients Development of technologies for diabetes Rising minimum or non-invasive products Growing awareness of diabetes care devices Development need for faster, safer and effective method of diagnosis and treatment of diabetes The restraining factors of Global Diabetes Care Devices Market are as follows: Expensive related with diagnosis and treatment Compensation issues and patent expiry This report provides: 1) An overview of the global market for Global Diabetes Care Devices Market and related technologies. 2) Analyses of global market trends, with data from 2013, estimates for 2014 and 2015, and projections of compound annual growth rates (CAGRs) through 2022. 3) Identifications of new market opportunities and targeted promotional plans for Global Diabetes Care Devices Market. 4) Discussion of research and development, and the demand for new products and new applications. 5) Comprehensive company profiles of major players in the industry. The Global Diabetes Care Devices Market has been segmented as below: By Glucose Monitoring Devices Analysis: Blood Glucose Meters Blood Glucose Test Strips Lancing Devices Continuous Glucose Monitoring Devices HbA1c Testing Kits By Insulin Delivery Devices Analysis: Insulin Pumps Insulin Syringes Insulin Pens By Type Analysis: Therapy Type Injectable Oral Drugs By Regional Analysis: North America Europe Asia-Pacific Rest of the World Reasons to Buy this Report: 1) Obtain the most up to date information available on all Global Diabetes Care Devices Market. 2) Identify growth segments and opportunities in the industry. 3) Facilitate decision making on the basis of strong historic and forecast of Global Diabetes Care Devices Market data. 4) Assess your competitor's refining portfolio and its evolution.

Latest Financial News for TNDM

In November 2011, the company received FDA clearance to market the t:slim Insulin Pump, the first ever touch-screen insulin pump.[7] In February 2013, the company received FDA clearance to market the t:connect Diabetes Management Application, a Mac and PC-compatible data management application that provides t:slim Pump users and their healthcare providers a way to display data from the pump and supported blood glucose meters on a cloud-based platform. In January 2015, Tandem announced FDA clearance of the t:flex Insulin Pump, the largest capacity insulin pump on the market. In July 2014, Tandem announced that it had submitted a PMA for the t:slim G4, which integrates t:slim Pump technology with the Dexcom G4 Platinum CGM System. This device was approved by the FDA in September 2015.The FDA approved a tool to update the software on Tandem's pumps in July, 2016. The Tandem Product Updater is designed to deliver software updates to Tandem's pumps to provide new features and interface improvements. In announcing the approval, Tandem stated that the first use of the new tool will be to update t:slim pumps which were shipped prior to April, 2015 with a new version of the firmware which speeds the loading process and offers other enhancements. In late October 2016, Tandem began shipping its next-generation pump platform, the t:slim X2. The X2 will receive updates via the Tandem Product Updater product, with planned updates initially including integration with Dexcom's G5 and G6 Continuous Glucose Monitors, and eventually the integration of closed-loop technology which Tandem licensed from TypeZero in July 2016

In 2006, a group of engineers recognized the need for new and improved methods of pumping insulin and incorporated as Phluid, Inc. In 2007, Kim Blickenstaff joined the organization as President and CEO, bringing his philosophy of using market research as the inspiration for product development and started on the development of the t:slim Insulin Pump. In 2008, this predecessor company became the newly incorporated Tandem Diabetes Care, Inc. that was formed with a focus on promoting a comprehensive, user-centric, and integrated approach to diabetes product development and customer care. Tandem Diabetes Care felt that incorporating enhanced ease of use and attractive design—often associated with consumer electronics development—would also encourage more patients to consider the clinical benefits of insulin pump therapy. Tandem Diabetes Care interviewed more than 4,000 insulin pump users and health care providers to design its first device, the t:slim Insulin Pump. In 2016, the company was ranked #39 on the Deloitte Fast 500 North America list

Iconic Australian surf brand Quiksilver is purchasing its hometown rival Billabong for $300 million. Kyles, Tylers, and Blakes everywhere are freaking out. That’s because if you didn’t wear a Billabong or Quiksilver shirt in sixth grade to complement your long hair and seashell necklace, you weren’t cool. But neither company has been especially cool lately. Billabong wiped out in 2013, admitting its brand was a thing of the past. And Quiksilver hung zero when it filed for bankruptcy in 2015. Luckily, PE shop Oaktree Capital was there to scoop up Quiksilver. And after two years of financial CPR, it’s hoping a Quiksilver-Billabong duo will be gnarly enough to bring back the glory days. All together, they’ll have 600 stores in 28 countries. Surf’s up. http://morningbrew.cmail20.com/t/j-l-okddrz-yhyuhjkhdk-ji/

Weinstein just keeps falling from grace. This time, the tarnished name is in the news as The Weinstein Company nears a sale for less than $500 million, roughly half of which is debt. Insult to injury: shareholders risk losing all equity. Of the 20 bids the film studio has received since December, six have made the short-list, including former Obama cabinet member Maria Contreras-Sweet. Some other contenders: production company Killer Content (supported by Abigail Disney), studio Lionsgate, and investment firm Shamrock Capital (founded by another Disney, Walt's nephew Roy). After co-chairman Harvey was fired following dozens of high-profile sexual assault and harassment allegations, Weinstein Co. found itself in cinema purgatorio. Its slate of upcoming releases—including drama Current War about Thomas Edison and George Westinghouse—is collecting dust while the studio tries to write a happier ending. And in Hollywood, timing is everything. While operating expenses and legal bills continue to pile up, Weinstein Co. may soon have no choice but to file for bankruptcy.

World News - Money

World News - Money

World News - Money

World News - Money

World News - Money

World News - Money

World News - Money

World News - Money

World News - Money

video-cnbcukfin-yahoopartner: The average annualized total return for the S&P 500 index over the past 90 years is 9.8 percent. For 2017, in just under half a year, the S&P 500’s total return is 9.7 percent. Looking at these facts side by side, it might seem the market has been twice as generous as usual so far this year, tempting a wary investor to back away from stocks or expect next to nothing more over the coming six months. Yet equity returns come in waves, not in metered doses. The market gets on a roll, overshoots, retrenches, and sometimes—as in the 18 months ended last November—just slides sideways. One of the market’s more intriguing and mischievous traits is that it rarely produces the long-term “average” return in a given calendar year. Looking now only at price returns (not counting dividends), a gain between five and 10 percent is one of the rarest results for stocks. According to data furnished by LPL Financial senior market strategist Ryan Detrick, in the 89 years from 1928 to 2016, only six finished with a gain in that range that we think of as a “typical” annual return. Source: LPL Financial More than a quarter of all years saw better than 20 percent appreciation. And Detrick notes, too, that the S&P 500 advanced 9.5 percent last year - and has never seen two straight years of gains between five and 10 percent. So, if the historical odds are against stocks just idling near this level for the next several months, which way are they likely to go? Strictly looking at past periods that closely resemble this one - quiet years in an uptrend, with plenty of new highs and good market breadth - the evidence points toward further gains in the second half. Yet the calm is increasingly likely to be interrupted by the sort of more noteworthy downdraft that we haven’t had in quite a while. When the S&P 500 was up at least 7.5 percent on its hundredth trading day of a year, as it was this year, it added to those gains through year-end 20 out of 23 times. And since 1950, when the S&P 500 has made at least 15 new all-time highs through May, it was far more likely to keep rising through December, and the average further gain over the final seven months was 7.7 percent, far better than the 4.5 percent average for June-December in all years. A slightly different screen by Sam Stovall of CFRA - testing for years with as many new highs and similar lack of volatility as 2017 - found a similarly heavy probability of generous further upside. The largest and most significant exception to these patterns came in 1987 - a year that began with powerful upside momentum, faltered in mid-summer, then crashed in October to wipe out the early-year gains. It’s a scary year to come up in the comparative analysis. But it’s also important to note the market was up a whopping 40 percent in the first seven months of that year - a ferocious blow-off rally. And stocks got very jumpy and started losing altitude badly in August. The crash did not blindside an otherwise placid tape. Still, this market has gone so long without even the sort of routine 5 percent pullback that visits even the best of years that even bullish investors should be checking their mirrors and blind spots. The recent wobble in big-cap tech stocks that dropped the Nasdaq 100 (NDX) index by 4.5 percent could foreshadow at least a mild gut check for the broader market. Investor Urban Carmel of the Fat Pitch blog notes, “In the past seven years, falls of more than 4 percent in NDX have preceded falls in SPY of at least 3 percent. That doesn’t sound like much, but it would be the largest drop so far in 2017.” Seasonal patterns, which have an iffy record in the past year or so, also suggest the market should get choppier pretty soon, for what that’s worth. The best way to prepare for what an inherently unpredictable market might deliver is to assess the weight of the evidence and remain open to a range of outcomes. Maybe if the market does keep chugging a good deal higher, it will finally deserve the “bubble” label (which it really doesn’t right now), and perhaps it will grow more unstable as it does so, and be hounded by a collicky credit market rather than the current stoic one. None of this is observable yet. One of the least welcome messages in the latter part of a bull market, with more than enough discomfiting headlines to go around, is “Don’t worry so much.” But, for better or worse, this is what the probabilities are suggesting at the moment. Sure, stout valuations today imply so-so returns over the long term. But, remember, the market bestows its returns in unpredictable gulps, not measured sips. World News - Money

Empire State Building - New York City - New York - USA (by nestor ferraro) World News - Money

World News - Money